Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | HTR1F | P30939 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19364893 | 0.84 | CYP1A2 (0.39) | GRM5FGFR4 | |
| SCHEMBL19365370 | 0.84 | PTGS1 (0.41) | GRM5FGFR4HTT | |
| SCHEMBL19365284 | 0.84 | BRD4 (0.40) | GRM5BRD4DEGS1 | |
| SCHEMBL19365313 | 0.83 | KMT2A (0.37) | FFAR2KDM4E | |
| SCHEMBL19365662 | 0.82 | HTR1F (0.36) | HTR1FKDM4EALDH1A1HTT | |
| SCHEMBL19365654 | 0.82 | HCRTR1 (0.44) | GRM5BRD4 | |
| SCHEMBL19670585 | 0.80 | FGFR4 (0.34) | GRM5FGFR4HTR1FBRD4 | |
| SCHEMBL19670246 | 0.80 | SCN9A (0.39) | FGFR4 | |
| SCHEMBL16238462 | 0.80 | DEGS1 (0.39) | GRM5FGFR4FFAR2AHRDEGS1 | |
| SCHEMBL19670420 | 0.79 | HDAC2 (0.42) | FGFR4KDM4EALDH1A1HTTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 4062/4885FGFR4 2275/4885HTR1F 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.